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What’s already known about this topic?  
There are only weak to moderate correlations between Psoriasis Area and Severity Index 
(PASI) and Dermatology life Quality Index (DLQI) scores. 
Factors other than area and severity may play a role in patients’ evaluations of their 
health-related quality of life (HRQOL).  
Patients perceive pain, itching, and scaling to be the most troubling aspects of their 
psoriasis. 
 
What does this study add? 
Both PASI response and improved psoriasis-related symptoms of pain, itching, and 
scaling have an important role for improvements in HRQOL and work and daily activity.  
Improvements in PASI, patient-reported symptoms, HRQOL, and work and daily activity 
were greater for those patients on secukinumab vs. ustekinumab. 
Differential effects of secukinumab vs. ustekinumab for treatment 
of psoriasis on quality of life, work productivity and activity 
impairment: a structural equation modelling analysis 
Purpose: This study examined direct and indirect (mediated) effects of 
secukinumab vs. ustekinumab on quality of life, work productivity, and 
activity impairment based on psoriasis severity and symptoms. 
Methods: Analyses were based on data from the CLEAR study. Structural 
equation modelling (SEM) examined the effects of secukinumab vs. 
ustekinumab on the Dermatology Life Quality Index (DLQI) and on the 
Work Productivity and Activity Impairment (WPAI) questionnaire using 
Psoriasis Area Severity Index (PASI) severity and symptoms (pain, 
itching, and scaling) as potential mediators. Analyses were conducted 
primarily for patients achieving PASI 90 response at week 16 (repeated at 
week 52) and for PASI 50, 75, and 100. 
Results: Results at weeks 16 and 52 showed that the effect of treatment on 
change in DLQI score was mediated by PASI 90 response and by 
improvements in itching and scaling. Achieving any PASI response as 
early as week 16 directly resulted in significantly better WPAI scores. At 
week 52, both PASI response and improvement in scaling directly resulted 
in significantly better WPAI scores. Pain, itching, and scaling were 
correlated (r = 0.51 to 0.68); improvement in any of these had a significant 
effect (directly or indirectly) on WPAI. All results favoured secukinumab 
over ustekinumab. 
Conclusion: The results underscore the important role of both PASI 
response and improved symptoms on improvements in health-related 
quality of life and work and daily activity in favour of secukinumab vs. 
ustekinumab. 
Keywords: psoriasis; health-related quality of life; work and activity 
impairment; structural equation modelling 
Introduction 
The appearance and lifelong, chronic nature of psoriasis result in considerable 
burden to patients [1] such as sleep impairment [2], depressive symptoms [3,4], 
negative self-esteem [1], and reduced work productivity. [5,6]. 
Assessment of psoriasis severity and response to treatment in clinical trials 
is typically made using the Psoriasis Area Severity Index (PASI) [7]. However, 
while PASI provides a composite assessment of the signs and extent of psoriasis, 
it does not yield information about the effect psoriasis has on patients’ lives [8]. 
The Dermatology Life Quality Index (DLQI) is the most commonly used 
instrument to assess the health-related quality of life (HRQOL) of patients with 
psoriasis [7,9]. However, increasing evidence confirms only weak to moderate 
correlations between PASI and DLQI [10,11]. This suggests that factors other 
than objective disease severity may play a role in patients’ evaluations of their 
HRQOL. Previous research has shown that patients perceive pain, itching, and 
scaling to be the most troubling aspects of their psoriasis [12,13]. These 
symptoms are correlated with PASI scores [14] and may affect HRQOL and work 
and activity impairment.  
In a head-to-head clinical trial for the treatment of moderate to severe 
psoriasis, the CLEAR study, secukinumab has demonstrated sustained greater 
efficacy versus ustekinumab in clearing skin through week 52; greater 
improvement in symptoms, HRQOL, work and activity impairment; and a 
comparable safety profile [15]. 
The present post hoc analysis from the CLEAR study explored how PASI 
response and psoriasis symptoms (pain, itching, and scaling) affect HRQOL and 
work and activity impairment using a sophisticated analytic method, structural 
equation modeling (SEM). Further, the analysis explored how these relationships 
differ between secukinumab and ustekinumab. 
Methods 
Data 
The data for these analyses came from CLEAR, a 52-week, multicenter, 
randomized, double-blind, head-to-head, parallel-group superiority trial in 
moderate to severe psoriasis. At baseline, data were available from 336 patients 
randomized to secukinumab and 339 randomized to ustekinumab. Details of study 
methods and efficacy/safety results have been previously reported.[15,16].  
Measures 
Psoriasis Area Severity Index (PASI) 
The PASI is a clinician-reported measure evaluating the head, trunk, upper limbs, 
and lower limbs for the severity and body surface area coverage of erythema, 
thickening (plaque elevation, induration), and scaling (desquamation) [17-19]. 
Improvement was assessed by the percentage of reduction in PASI total score 
from baseline at each time point, with specific thresholds of 50% (PASI 50), 75% 
(PASI 75), 90% (PASI 90) and 100% (PASI 100) reductions being the main 
criteria for improvement. The PASI response at weeks 16 and 52 were used for 
this analysis. 
Dermatology Life Quality Index (DLQI) 
The DLQI is a 10-item patient-reported measure evaluating the extent to which 
quality of life (QOL) has been affected by skin problems in the previous week 
[20]. Total and subscale scores (Symptoms and Feelings, Daily Activities, 
Leisure, Work and School, Personal Relationships, and Treatment) are computed. 
The total DLQI score ranges from 0 (no effect on patient’s life) to 30 (extremely 
large effect on patient’s life). The change in DLQI total score at weeks 16 and 52 
was used for this analysis. 
Work Productivity and Activity Impairment–Psoriasis (WPAI) 
The WPAI is a self-administered questionnaire comprised of six questions 
regarding the effects of psoriasis on the subject’s ability to work and perform 
regular activities and is based on their experiences in the previous 7 days [21]. 
Scores were calculated for the percent of impairment in daily activities or while 
working (“presenteeism”) and work time missed (“absenteeism”). The WPAI 
scores from weeks 16 and 52 were used in this analysis. 
Patient’s assessment of psoriasis-related pain, itching, and scaling 
A self-administered, 11-point numeric rating scale (0-10) was used to evaluate the 
patient’s assessment of pain, itching, and scaling over the past 24 hours. 
Respondents answered three questions for the assessment of pain, itching, and 
scaling: “Overall, how severe was your psoriasis-related pain/itching/scaling over 
the past 24 hours?” A score of 0 represented the absence or null end of the pain, 
itching, or scale intensity (i.e., no pain, itching, or scaling) and a score of 10 
represented the other extreme of pain, itching, or scaling intensity (i.e., pain, 
itching, or scaling as bad as it could be). Symptom severity scores for psoriasis-
related pain, itching, and scaling at weeks 16 and 52 were used in this analysis. 
Baseline Covariates 
The following covariates, known to potentially drive HRQOL, were also included 
in the present analyses: age and gender of the patient; body mass index; duration 
of psoriasis; presence of psoriatic arthritis at baseline; and previous use of 
biologics/systemics before treatment with secukinumab or ustekinumab in the 
CLEAR study. 
Analyses 
The analyses were carried out using SEM, a type of path analysis that involves the 
use of latent variable (i.e., unobserved variables; also called factors) and manifest 
variables (i.e., observed variables) to assess the relationships between multiple 
patient-relevant outcomes simultaneously. [22,23] We used SEM to assess the 
direct and indirect (i.e., mediated) differential effects of psoriasis treatment 
(secukinumab vs. ustekinumab), covariates, PASI response, and patient-reported 
psoriasis-related symptoms (pain, itching, and scaling) on change in DLQI scores 
from baseline at weeks 16 and 52, and on WPAI scores at weeks 16 and 52. We 
present PASI 90 results since PASI 90 was the primary efficacy endpoint of the 
CLEAR study, although the SEM analyses were replicated for PASI 50, 75, and 
100 responses. 
We hypothesized in the DLQI model that the DLQI Symptoms and 
Feelings (DLQI-SF) subscale was antecedent to a DLQI Total (Revised) 
“subscale” combining the remaining five DLQI subscales (Daily Activities, 
Leisure, Work and School, Personal Relationships, and Treatment subscales; 
Figure 1). The logic underlying this set of relationships was that changes in PASI 
response and psoriasis symptoms would first affect the DLQI-SF subscale 
(measured by the questions “Over the last week, how itchy, sore, painful, or 
stinging has your skin been?” and “Over the last week, how embarrassed or self-
conscious have you been because of your skin?”); the DLQI-SF subscale would 
then, in turn, affect the remaining subscales of the DLQI. The five remaining 
subscales were modelled as alternative measures of a revised latent variable for 
the DLQI Total.  
Three WPAI scores were considered in the SEM model for WPAI: percent 
of impairment in daily activities, percent of impairment while working 
(“presenteeism”), and work time missed (“absenteeism”) in the previous 7 days 
(Figure 2). 
Goodness-of-fit tests were used to assess how closely the hypothesized, 
model-implied relationships fit or represented those in the CLEAR data. In 
addition to the fit indices, examination of results focused on standardized 
coefficients (β [i.e., betas] ranging from –1 through 0 to +1, where –1 is a perfect 
inverse relationship between variables, 0 is no relationship, and +1 is a perfect 
positive relationship; standardized coefficients are interpreted in a similar way as 
correlation coefficients); this approach enabled direct comparison of the strength 
of relationships between the variables included in the DLQI and the WPAI 
models. 
Results 
Baseline comparisons 
Baseline characteristics and patient-reported outcome scores for patients in the 
two treatment arms of the CLEAR study were similar (Table 1). These data have 
been presented elsewhere [16]. 
Change in the DLQI score from Baseline to Weeks 16 and 52 
Results for the models of the change in DLQI total score from baseline to 
week 16 and from baseline to week 52 are presented in Figure 3 and Figure 4, 
respectively. Goodness-of-fit statistics for the DLQI models were all excellent, 
indicating that the relationships hypothesized in Figure 1 are representative of 
those in the CLEAR data. Moreover, the fit statistics were much better for the 
model where DLQI-SF was antecedent to the DLQI Total (Revised) [See 
Supplemental Information]. This confirms the model hypothesis that if patients 
feel that their itchy, sore, painful, or stinging skin has improved, or if patients feel 
less embarrassed or less self-conscious about their skin, they will be more likely 
to carry out daily activities and personal relationships. 
Results of the DLQI model at week 16 showed that the impact of psoriasis 
treatment on DLQI was not direct but was mediated by both PASI response and 
psoriasis-related symptoms. 
Compared with those treated with ustekinumab, patients treated with 
secukinumab were significantly more likely to achieve PASI 50/75/90/100 
response (β = –0.08, –0.14, –0.22, –0.17, respectively). Achieving PASI 75 or 90 
(but not PASI 50 or PASI 100) significantly improved the DLQI-SF subscale 
which in turn significantly improved the DLQI Total (Revised) subscale (i.e., the 
combined total of the other five DLQI subscales). Similarly, improvements in 
pain, itching, and scaling also significantly improved the DLQI-SF subscale (β = 
0.18, 0.41, 0.21; all P < 0.05), which in turn significantly improved the DLQI 
Total (Revised) subscale (β = 0.50; P < 0.05) in favour of secukinumab over 
ustekinumab. Improvement in itching had the largest effect on the DLQI-SF 
subscale and on the DLQI Total (Revised) via the DLQI-SF subscale, although 
pain and scaling were also significant. The DLQI Total (Revised) subscale was 
important to patients, with Leisure, Daily Activities, and Personal Relationships 
subscales being the most important (i.e., they had the highest standardized 
coefficients). 
Similar results were seen with the DLQI models at Week 52. 
WPAI Scores at Week 16 and Week 52 
Results for the WPAI models at week 16 and at week 52 are presented in Figure 5 
and Figure 6, respectively. Goodness-of-fit statistics for the WPAI models were 
all excellent, indicating that the hypothesized relationships in Figure 2 reflect the 
data very well. 
Results of the WPAI models at week 16 showed more complex 
relationships between the different variables than was seen with the DLQI models 
and that the impact of psoriasis treatment on WPAI was not direct but was 
mediated by PASI response. 
Psoriasis treatment (β = –0.215) and scaling (β = –0.257) directly 
improved PASI 90 response, and patients treated with secukinumab were more 
likely to achieve PASI 90 response than those treated with ustekinumab. The 
effects of improvement in psoriasis symptoms on WPAI scores were completely 
indirect and were mediated by the improvement in PASI response. When scaling 
improved, pain and itching improved, and this improvement was more likely for 
those treated with secukinumab vs. ustekinumab. Compared with ustekinumab, 
treatment with secukinumab indirectly and significantly improved pain and 
itching (r ≈ 0.07 and 0.09, respectively) via improvements in scaling and, in turn, 
the observed correlations between improvements in scaling and improvements in 
pain and itching.  
Achieving PASI 90 response directly resulted in less WPAI activity 
impairment (β = –0.215) and presenteeism (β = –0.2). Because WPAI activity 
impairment and presenteeism are significantly correlated with absenteeism in this 
model, achieving PASI 90 response also resulted in less absenteeism. Given that 
scaling has a direct effect on PASI response, improvement in scaling indirectly 
resulted in lower WPAI activity impairment and less presenteeism. 
Results of the models at week 16 were similar for all PASI responses. 
The results of the WPAI models at week 52 were somewhat different, with 
both PASI response and symptoms mediating the effects of psoriasis treatment on 
WPAI scores. 
Patients on secukinumab experienced greater improvements in pain, 
itching, and scaling, and were more likely to achieve PASI 90 response than those 
on ustekinumab. Improvement in scaling and the achievement of PASI 90 
response directly resulted in lower WPAI activity impairment (β = 0.115, –0.223, 
respectively), and less presenteeism at week 52 (β = 0.126, –0.236, respectively). 
Improvement in scaling and the achievement of PASI 90 response indirectly 
resulted in less absenteeism at week 52 because absenteeism was correlated with 
WPAI activity impairment (r = 0.264) and presenteeism (r = 0.305) in this model. 
Pain and itching were directly related to psoriasis treatment and were correlated 
with scaling (which had direct effects on WPAI activity impairment and 
presenteeism); therefore, pain and itching indirectly resulted in lower WPAI 
activity impairment, less presenteeism, and less absenteeism at week 52. 
Results of the models at week 52 were similar for all PASI responses. 
Discussion 
This post hoc analysis of the CLEAR 52-week data indicate that the relationships 
among psoriasis treatment, PASI response, and psoriasis-related symptoms and 
HRQOL and work and activity impairment are complex, often involving indirect 
but significant relationships. The SEM analyses demonstrated that the effect of 
psoriasis treatment on HRQOL and WPAI are mediated by both PASI response 
and improvements in patient-reported psoriasis-related pain, itching, and scaling 
symptoms. Secukinumab showed superior efficacy in clearing skin and relieving 
symptoms, a finding which resulted in greater positive impact of secukinumab on 
HRQOL and on WPAI versus ustekinumab.  
Clear skin is the ultimate treatment goal and is associated with improved 
HRQOL. Previously, the effects of improvement in psoriasis symptoms on 
HRQOL and WPAI were unclear. This analysis provides insight on the 
importance of relieving bothersome psoriasis symptoms for patients’ lives. 
Griffiths and colleagues [10] reported weak to moderate correlations between 
DLQI and PASI total scores and noted that changes in QOL do not appear to be 
captured by PASI or its subscales. Our results demonstrate that, in alignment with 
this research, factors other than PASI influence HRQOL and, more specifically, 
that patient-assessed psoriasis symptoms play an important role in affecting 
patient outcomes. Whereas Leonardi and colleagues [24] focused on the effects of 
pruritus severity, the present study included three key psoriasis symptoms noted 
by patients [12,13] and demonstrated their key role in the patient experience with 
psoriasis. 
In 2013, Lewis-Beck and colleagues [25] were first to inform on the 
presence of direct relationship between psoriasis symptom (pain, itching, and 
scaling) severity and HRQOL and work and activity impairment among patients 
with moderate to severe psoriasis using SEM. However the present analyses go 
well beyond this research by using a full structural equation model that 
simultaneously estimates all hypothesized relationships and evaluates the fit of the 
hypothesized model to the observed data in the CLEAR study without having to 
use a two-stage analytic approach. Moreover, our models investigate the 
differential effects of two active treatments for moderate to severe psoriasis and 
the effects at different time points, which is rarely explored in SEM analyses to 
our knowledge.  
The confirmation of the hypothesis that the Symptoms and Feelings 
subscale was antecedent to a latent variable (factor) representing the remaining 
five subscales of the DLQI Total (Revised) was a notable result. The results of the 
SEM analyses suggested that improving skin clearance and psoriasis symptoms 
will first improve the patients’ experience with itchy, sore, painful, or stinging 
skin and embarrassment with skin before improving other domains of HRQOL, 
such as daily activities or personal relationships. Although this seems logical, this 
measurement model of the DLQI should be explored in future research since it 
appears to be a novel conception of this measure. 
Interestingly, the effects of improvement in psoriasis symptoms on WPAI 
scores were mediated by improvement in PASI response in the models at week 
16, but they directly affected WPAI scores at a later time point (i.e., week 52). 
This finding may indicate that patients first experience the effects of clear skin on 
their work and activities followed by the additional effects of improvements in 
their psoriasis symptoms. 
We did not find a relationship between PASI 50/100 responses and 
changes in the DLQI-SF subscale at week 16, or between PASI 50 response and 
the DLQI-SF subscale at week 52. For PASI 50 response, this may be caused by 
the large skew in the distribution of patients, as almost 95% of patients had 
attained PASI 50 at both time points. Thus, there was little variability for use as a 
reliable predictor. It is unclear why we did not find a relationship between PASI 
100 response and changes in the DLQI-SF subscale at week 16 whereas a 
relationship was found at week 52. In contrast, all PASI responses were directly 
related to WPAI scores at week 16 and week 52. It may be explained by the use of 
actual scores for WPAI rather than changes in scores from baseline, as with the 
DLQI and PASI. The rationale behind using actual scores in the SEM rather than 
the change of scores from baseline was based on the fact that the WPAI collects 
the work and activity experience of the patient during the past 7 days, excluding 
the current day. We believe it makes more sense to focus on the WPAI scores at 
weeks 16 and 52, when the measure has a one-week recall at both time points. 
We explored whether a psychological variable such as depression could 
play a role in explaining some of these relationships following recent findings 
showing an increased likelihood of depressive symptoms or clinical depression 
among patients with psoriasis, which may have some etiology in the systemic 
inflammatory condition that increases risk of brain inflammation [4,26,27]. The 
only measure of depression/anxiety available from the CLEAR study is the single 
item from the EuroQol EQ-5D that asks about the extent to which the patient feels 
anxious or depressed today. As an example, the results of the models of the WPAI 
that included the EQ-5D anxiety/depression variable showed that improvements 
in pain and scaling directly resulted in less anxiety/depression, which in turn 
resulted in less activity impairment and impairment while working 
(presenteeism). However, an argument could be made that improvements in the 
WPAI also led to improvement of the EQ-5D anxiety/depression domain. It is not 
clear if anxiety or depression is a mediating variable with effects on work and 
activity impairment or if it is itself an outcome of these QOL domains. Further 
work is needed to understand the role of anxiety/depression in patients’ outcomes. 
Some limitations in the current study are worth noting. As with any SEM, 
there are implied causal relationships with these models and interpretations of 
many of the paths in these models are that of causal relationships. However, time 
ordering was built into the DLQI analyses by using PASI score at weeks 16 and 
52, and change from baseline in psoriasis symptoms and DLQI scores. For the 
WPAI analyses, the WPAI scores at weeks 16 or 52 (reflecting the previous 7 
days) were used as outcome variables, along with the covariates of PASI 
responses from baseline to weeks 16 and 52, and change from baseline in 
psoriasis symptoms. There is nothing inherently wrong with this approach, 
particularly when the hypothesized relationships are based on sound logic 
supported by significant empirical results. Nonetheless, firm causal conclusions 
must be accepted tentatively.  
A second possible limitation is that the CLEAR study was a clinical trial, 
with specific inclusion/exclusion criteria and controls. It would be valuable to 
know whether these same relationships hold in real-world situations. In addition, 
analyses were limited to the variables available in the CLEAR study; other 
relevant variables might play a role in these relationships, but were not available 
for these analyses. 
The DLQI and WPAI were analysed separately (i.e., in separate models) 
for two reasons: (1) the models became complex analytically because there were 
many domains of HRQOL outcomes between the two measures, some of which 
overlapped in content (e.g., DLQI Daily Activities and Work and School with the 
WPAI Activity Impairment and Work Impairment); and (2) the combined models 
would be visually complex and it would be difficult to see individual paths. Thus, 
we feel the approach used in this analysis provides the clearest presentation of the 
complex relationships and yields the same conclusions. 
The SEM analyses utilized here represent a powerful and informative 
analytic method that has helped us obtain a detailed understanding of the 
differential direct and indirect effects of secukinumab versus ustekinumab on 
multiple patient-relevant outcomes simultaneously. These analyses underscore the 
important role of both clear skin and improved psoriasis-related symptoms in 
affecting the lives of patients with moderate to severe psoriasis; these findings 
also produce explanatory insights into the greater impact of secukinumab 
treatment versus ustekinumab in improving patient-reported outcomes. 
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Tables 
Table 1. Baseline Demographics and PRO Scores of the Two Treatment Groups 
 
Secukinumab  
(N = 336) 
Ustekinumab  
(N = 339) 
Age, years, mean (SD) 45.2 (13.96) 44.6 (13.67) 
Male, n (%) 229 (68.0) 252 (74.3) 
Weight (kg) 87.4 (19.95) 87.2 (22.11) 
Currently employed at baseline, n (%) 228 (67.7) 225 (66.4) 
Patient-reported outcomes    
DLQI total score  13.4 (7.63) 13.2 (7.57) 
WPAI: Absenteeism 5.39 (14.986) 5.96 (15.672) 
WPAI: Presenteeism 27.31 (26.095) 26.17 (24.304) 
WPAI: Activity impairment  36.87(29.942) 35.83 (29.186) 
DLQI = Dermatology Life Quality Index; PRO = patient-reported outcome; 
SD = standard deviation; WPAI = Work Productivity and Activity Impairment 
Legends and Figures
Figure 1. Hypothesized Structural Equation Model of Predictors of the DLQI 
BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area Severity Index. 
Figure 2. Hypothesized Structural Equation Model of Predictors of the WPAI 
BMI = body mass index; PASI = Psoriasis Area Severity Index; WPAI = Work Productivity and Activity Impairment. 
Figure 3. PASI 90, Changes in Itching, Pain, and Scaling with Changes in DLQI at Week 16 
BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area Severity Index; PSA = psoriatic arthritis; Tx = treatment. 
Figure 4. PASI 90, Changes in Itching, Pain, and Scaling with Changes in DLQI at Week 52 
 
BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index; PSA = psoriatic arthritis; Tx = treatment.  
Note: For both Figures 3 and 4, only paths significant at P ≤ 0.05 are shown. Variables in squares = observed variables; variable in a circle = latent variable. Direct effects are 
depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable 
having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable.  
Figure 5. PASI 90 Changes in Itching, Pain, and Scaling With WPAI Activity Impairment, Work Impairment, and Work Time Missed at Week 16 
BMI = body mass index; PASI = Psoriasis Area and Severity Index; PSA = psoriatic arthritis; Tx = treatment; WPAI = Work Productivity and Activity Impairment.  
Figure 6. PASI 90 Changes in Itching, Pain, and Scaling With WPAI Activity Impairment, Work Impairment, and Work Time Missed at Week 52 
 
BMI = body mass index; PASI = Psoriasis Area and Severity Index; PSA = psoriatic arthritis; Tx = treatment; WPAI = Work Productivity and Activity Impairment. 
Note: For both Figures 5 and 6, only paths significant at P ≤ 0.05 are shown. Variables in squares = observed variables. Direct effects are depicted as an arrow emanating from 
an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an 
independent variable but also pointing to yet another dependent variable.  
